Important News and Results from Two Companies in the Prohost Portfolio

Important News and Results from Akero Therapeutics
Akero Therapeutics (AKRO) announced that full results of the main portion of its Phase 2a BALANCED trial in biopsy-confirmed NASH patients with F1-F3 fibrosis have been published in Nature Medicine. The study shows investigational NASH Drug Efruxifermin (EFX) reduced liver fat to normal levels and reversed fibrosis after 16 weeks . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.